Touching the lives of an average 110 people each day in Aotearoa, traumatic brain injury (TBI) is much more common than any of us would like it to be.

When you scratch an itch, something tells your brain when to stop. That moment of relief, when scratching feels "enough," is not accidental. Scientists have now identified a key molecular and neural mechanism behind this built-in braking system, shedding new light on how the body regulates itch and why this control fails in chronic conditions.

Researchers at Örebro University have identified blood markers that can indicate who is at risk of developing ulcerative colitis—a chronic inflammatory bowel disease—later in life. These markers can be present for many years before the first symptoms appear. In their study published in the Journal of Crohn's and Colitis, the researchers analyzed blood samples from large population studies to identify a specific antibody called anti-integrin αvβ6.

For adults with asthma, having fans, air purifiers or other ventilation and exhaust systems - especially in kitchens and bathrooms - is one of the best ways to reduce the risk of flare-ups at home.

A single exposure to a toxic fungicide during pregnancy can increase the risk of disease for 20 subsequent generations - with inherited health problems worsening many generations after exposure.

A new study provides hope that smarter timing of cancer treatments could improve cure rates.

A new study of more than 1,500 boys and men in Canada and the United States suggests that social media may play a meaningful role in shaping intentions to use anabolic-androgenic steroids (AAS), particularly when users are exposed to muscularity-focused content and engage in body comparisons online.

The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a future clinical trial in cutaneous sarcoidosis.

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

Adults with intellectual and developmental disabilities, such as autism and Down syndrome, experience substantially higher rates of anxiety and depression than the general population of adults, researchers reported today in JAMA Network Open.